Payment For Outcomes Key To EU Market Access for Yescarta
Executive Summary
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.
You may also be interested in...
EU Must Adopt Innovative Drugs & AI ‘At Scale’ To Plug Cancer Care Gaps
European countries should establish “implementation budgets” to fund innovative cancer therapies and leverage technologies such as AI in drug R&D to meet the rising demand for cancer care, pharmaceutical industry representatives say.
Scottish HTA Reverses No For Yescarta
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.